S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
NASDAQ:AVDL

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

$15.96
-0.19 (-1.18%)
(As of 04/11/2024 ET)
Today's Range
$15.26
$16.38
50-Day Range
$12.55
$17.22
52-Week Range
$9.34
$17.47
Volume
981,311 shs
Average Volume
580,055 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.57

Avadel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
41.4% Upside
$22.57 Price Target
Short Interest
Bearish
11.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of Avadel Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$29,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.46) to $0.83 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.60 out of 5 stars

Medical Sector

808th out of 2,787 stocks

Pharmaceutical Preparations Industry

334th out of 1,245 stocks

AVDL stock logo

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Stock Price History

AVDL Stock News Headlines

Weiss issues 'Buy' on AI sleeper stock
Based on our Weiss Ratings, we’ve issued a “Buy” on an under-the-radar AI stock. And we share the details at our Artificial Intelligence Town Hall ….
AVDL Apr 2024 15.000 call
Weiss issues 'Buy' on AI sleeper stock
Based on our Weiss Ratings, we’ve issued a “Buy” on an under-the-radar AI stock. And we share the details at our Artificial Intelligence Town Hall ….
AVDL Apr 2024 25.000 call
AVDL Apr 2024 10.000 put
AVDL Mar 2024 5.000 put
Avadel Pharmaceuticals Q4 2023 Earnings Preview
AVDL Jan 2025 20.000 call
Avadel Pharmaceuticals PLC ADR
AVDL Mar 2024 12.500 call
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
4/12/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AVDL
Employees
154
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$22.57
High Stock Price Target
$29.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+41.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-160,280,000.00
Pretax Margin
-574.96%

Debt

Sales & Book Value

Annual Sales
$27.96 million
Book Value
$0.98 per share

Miscellaneous

Free Float
86,954,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
1.60

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Gregory J. Divis Jr. (Age 57)
    CEO & Director
    Comp: $753.69k
  • Mr. Thomas S. McHugh (Age 59)
    Senior VP, Principal Financial and Accounting Officer & CFO
    Comp: $526k
  • Mr. Richard J. Kim (Age 55)
    Chief Commercial Officer
    Comp: $548.44k
  • Mr. Jerad G. Seurer
    General Counsel & Company Secretary
  • Mr. Gregory J. Davis (Age 59)
    VP of Corporate and Business Development
  • Mr. Mark W. Elrod
    Vice President of Sales
  • Ms. Angie Woods
    Vice President of People & Culture
  • Dr. Jordan S. Dubow M.D. (Age 45)
    Consultant
    Comp: $727.93k
  • Dr. Jason M. Vaughn
    Senior Vice President of Technical Operations
  • Ms. Jennifer Gudeman PharmD
    Senior Vice President of Medical & Clinical Affairs

AVDL Stock Analysis - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price target for 2024?

7 brokers have issued 12-month price objectives for Avadel Pharmaceuticals' shares. Their AVDL share price targets range from $16.00 to $29.00. On average, they anticipate the company's share price to reach $22.57 in the next year. This suggests a possible upside of 41.4% from the stock's current price.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2024?

Avadel Pharmaceuticals' stock was trading at $14.12 at the beginning of the year. Since then, AVDL shares have increased by 13.0% and is now trading at $15.96.
View the best growth stocks for 2024 here
.

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AVDL earnings forecast
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its quarterly earnings results on Monday, March, 4th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.04. The business had revenue of $19.45 million for the quarter, compared to the consensus estimate of $17.41 million. During the same period last year, the business earned ($0.44) EPS.

What ETFs hold Avadel Pharmaceuticals' stock?

ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVDL) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners